NDA 212516 · Sun Pharm
Drizalma Sprinkle
Duloxetine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jul 19, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
410
121 Phase 3, 33 recruiting
FAERS reports
52,942
38,285 serious, 5,746 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants (5.1) • Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors (5.1)
What it is approved for
From the label in effect May 14, 2024.
DRIZALMA SPRINKLE is indicated for the treatment of: • Major Depressive Disorder in adults • Generalized Anxiety Disorder in adults and pediatric patients 7 years of age and older • Diabetic Peripheral Neuropathy in adults • Fibromyalgia in adults • Chronic Musculoskeletal Pain in adults Additional pediatric use information is approved for Eli Lilly and Company, Inc.’s CYMBALTA (duloxetine delayed-release capsules). However, due to Eli Lilly and Company Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. DRIZALMA SPRINKLE is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of following conditions: • Major Depressive Disorder (MDD) in adults (1) • Generalized Anxiety Disorder (GAD) in adults and pediatric patients ages 7 years of age and older (1) • Diabetic Peripheral Neuropathic Pain (DPNP) in adults (1) • Fibromyalgia (FM) in adults (1) • Chronic Musculoskeletal Pain in adults (1)
Mechanism: Although the exact mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2021 Supplement 2 · Efficacy LabelLetter
- Jul 19, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
4 products under this application
- DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 40MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
- DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 20MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
- DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 60MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
- DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 30MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Duloxetine" as an intervention, any sponsor and status, largest first.
Eli Lilly and CompanyEli Lilly (LLY)
NCT00479726 · 8,000 participants · Start Aug 2004
Drug: duloxetine hydrochloride · For: Major Depressive Disorder
Sites: Indianapolis, Indiana
Eli Lilly and CompanyEli Lilly (LLY)
NCT00190905 · 4,000 participants · Start Feb 2004
Drug: duloxetine HCl · For: Stress Urinary Incontinence
Sites: Indianapolis, Indiana
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary IncontinencePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00190996 · 2,765 participants · Start Jan 2003
Drug: Duloxetine Hydrochloride; placebo · For: Urinary Incontinence, Stress
Sites: Surrey, United Kingdom
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,198
- fatigue3,892
- nausea3,793
- off label use3,210
- pain2,934
- headache2,804
- diarrhoea2,737
- dizziness2,319
- fall2,246
- vomiting2,032
- toxicity to various agents1,892
- arthralgia1,876
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 23 |
| 2006 | 42 |
| 2007 | 72 |
| 2008 | 145 |
| 2009 | 92 |
| 2010 | 129 |
| 2011 | 149 |
| 2012 | 124 |
| 2013 | 382 |
| 2014 | 1,019 |
| 2015 | 1,785 |
| 2016 | 2,557 |
| 2017 | 3,266 |
| 2018 | 4,324 |
| 2019 | 5,068 |
| 2020 | 5,408 |
| 2021 | 4,825 |
| 2022 | 4,822 |
| 2023 | 4,722 |
| 2024 | 4,707 |
| 2025 | 5,172 |
| 2026 | 4,109 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Drizalma Sprinkle (Duloxetine HCl)
2024 spending
$1.2M
Beneficiaries
2,478
6,429 claims
Per beneficiary
$480
$7.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,834,392 |
| 2021 | $4,146,026 |
| 2022 | $45,630 |
| 2023 | $9,375 |
| 2024 | $1,188,637 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
Pillinger T, Arumuham A, McCutcheon RA, et al. · Lancet 2025 · Network Meta-Analysis, Systematic Review
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis.
Migliorini F, Maffulli N, Eschweiler J, et al. · J Orthop Surg Res 2023 · Meta-Analysis, Systematic Review
- Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.
Tesfaye S, Sloan G, Petrie J, et al. · Lancet 2022 · Multicenter Study, Randomized Controlled Trial
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis.
Chow R, Novosel M, So OW, et al. · BMJ Support Palliat Care 2023 · Meta-Analysis, Systematic Review
Sponsor: Sun Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.